CClinicalTrials.gg
RecruitingNCT06543979Updated Oct 9, 2024

Anorectal Manometery in Pediatric Chronic Refractory Constipation

A Phase 1/2 interventional study of lubiprostone , single arm and biofeed back sessions in Chronic Constipation, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Ain Shams University · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
4 Years to 16 Years
Sex
All
01

Study summary

Anorectal manometry and high-resolution anorectal manometry (HRAM) are becoming the investigation of choice for understanding the pathophysiology of chronic constipation with or without fecal incontenance in children in many institutions. In high resolution anorectal manometery we are able to gain information whether the symptoms are related to sphincter dysfunction, impaired sensation, or pelvic floor dyssynergia

Read the detailed description

Primary objective: To assess different patterns of anorectal manometry in children with chronic refractory constipation with or without fecal incontinence.

Secondary objective: To determine the effectiveness of different modalities of treatment of chronic refractory constipation based on the anorectal findings. To assess the safety ,tolerability and effectiveness of lubiprostone in pediatric age group with chronic refractory constipation. To assess the effect of elimination of cow milk products in patient with chronic refractory constipation.

02

Conditions studied

  • Chronic Constipation

Browse trials for

03

In context

Constipation

1,018 studies on the registry are indexed under Constipation; 139 are open to participants now.

This study's planned enrollment of 60 is below the median of 80 across 850 interventional studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Children and adolescents aged from 4 to 16 years.
  2. Participants fulfilling Rome IV criteria for the diagnosis of functional constipation.

    At least 2 of the following present at least once per week for at least 1 month:

    • 2 or fewer defecations in the toilet per week
    • At least 1 episode of fecal incontinence per week
    • History of retentive posturing or excessive volitional stool retention
    • History of painful or hard bowel movements
    • Presence of a large fecal mass in the rectum
    • History of large-diameter stools that may obstruct the toilet The symptoms cannot be fully explained by another medical condition (Hyams et al., 2016).
  3. Participants who have chronic refractory constipation. Chronic refractory constipation (CRC) is defined as children who are unable to pass stools in spite of being on maximum laxative therapy and require daily rectal stimulation in the form of enemas or suppositories to pass stools 4-Is willing and able to keep a diary on his/her own and willing and able to complete a questionnaire.

5-The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  • participants who have anorectal malformation
  • participants who have neurological disease affecting lower limbs
  • Has a history of hypersensitivity or allergies to lubiprostone
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    single arm as all participant will receive the treatment

    all participant will receive lubiprostone

    Drug: lubiprostone , single arm · Procedure: biofeed back sessions · Procedure: botox injection

Interventions

  • Druglubiprostone , single arm

    laxative

    Also known as: lubicont

  • Procedurebiofeed back sessions

    Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations

  • Procedurebotox injection

    Botulinum toxin injection for participants suffering from elevated anal canal pressure

06

What researchers measure

Primary outcomes

  1. To evaluate the manometric parameters in children with chronic refractory constipation

    To measure the percent of the most common manometric parameters in children with chronic refractory constipation e.g dyssengeric defecation and reduced rectal sensetivity and anal sphincter dysfunction.

    Time frame: 1 year

  2. evaluate the efficacy of oral administration of lubiprostone 8 and 24 μg once daily for 4 weeks in participants with chronic refractory constipation

    Spontaneous Bowel Movement (SBM) Frequency at Week 1,2,3 and 4 A SBM was defined as any bowel movement (BM) that does not occur within 24 hours after rescue medication use (laxative, suppository, or enema). Participants will be given a diary to complete at home where they will record all details of each SBM including the consistency of the stool and the difficulty they have in passing it.

    Time frame: 1 month

Secondary outcomes

  1. To determine the effect of biofeed back sessions in children with dyssengeric defecation and in children with rectal hyposensetivity

    Participants with chronic refractory constipation and manometry parameters showed dyssengeric defecation or hyposensitivity will receive biofeedback sessions and the investigators measure the difference in bowel management scoring tool before and after the biofeedback sessions the higher the score the worest the condition

    Time frame: 3 months

  2. To determine the effect of cow milk protein free diet on chronic refractory constipation in children

    Participants will receive cow milk free diet for 4 weeks and investigators measure the difference in bowel management scoring tool before and after cow milk free diet the higher the score the worest the condition

    Time frame: 1 month

  3. To determine the effect of botulinum toxin injection in children with elevated anal canal resting pressure

    Participants with chronic refractory and manometric parameters showed high anal canal resting pressure will have botulinum toxin injection and investigators measure the difference in bowel management scoring tool before and after the injection the higher the score the worest the condition

    Time frame: 3 month

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06543979
Lead sponsor
Ain Shams University
Responsible party
asmaa abdelnaby (assistant lecturer of pediatrics, Ain Shams University) — Principal investigator
First posted
Aug 9, 2024
Start date
Sep 7, 2024
Primary completion
Sep 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Oct 9, 2024

Study contacts

asmaa abdelnaby mohamed soliman, master
Contact
samka2015.abdelnaby@gmail.com
+2001070689789
yosra mohamed mohsen awad, MD
Contact
01001831590
asmaa abdelnaby mohamed soliman, master
principal investigator · assistant lecturer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion